Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.

Journal of medical virology - 1 Nov 2014

Boglione Lucio, Cardellino Chiara Simona, De Nicolò Amedeo, Cariti Giuseppe, Di Perri Giovanni, D'Avolio Antonio

Abstract excerpt

The role of measurement of hepatitis B "s" antigen (HBsAg) during the therapy with oral nucleos(t)ide analogues is still debatable. The HBsAg declines after 3 years of therapy with entecavir (ETV) was investigated among patients affected by hepatitis B virus (HBV), e antigen (HBeAg)-negative and genotypes A, D and E. A prospective cohort of 123 patients was enrolled consecutively from April 2007 to May 2010 with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to DNA, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Hepatitis B virus

Share to Viral Load

Source

Identifiers

PMID: 25131947
DOI: 10.1002/jmv.24038

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.PMID 25131947Read ↗

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.Semantic proximity Read ↗

Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.Semantic proximity Read ↗

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.Semantic proximity Read ↗

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.Semantic proximity Read ↗

Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.Semantic proximity Read ↗

Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.Semantic proximity Read ↗

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.Semantic proximity Read ↗

Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.Semantic proximity Read ↗

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.Semantic proximity Read ↗

Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.Semantic proximity Read ↗

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.Semantic proximity Read ↗

Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.